Search

Your search keyword '"Juan Ángel Ferrer"' showing total 11 results
Start Over Author "Juan Ángel Ferrer" Publication Type Academic Journals
11 results on '"Juan Ángel Ferrer"'

1. Noticias y revisión bibliográfica

Author

Mª Luisa González Márquez, Javier Reinares Ortiz de Villajos, Inmaculada Izquierdo Moya, Pedro García López, Juan Ángel Ferrer Azcona, and Óscar Martínez Jiménez

Subjects
Medicine
Abstract

No disponible

Published
2024

2. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry

Author

Margalida Calafat, Paola Torres, Joan Tosca-Cuquerella, Rubén Sánchez-Aldehuelo, Montserrat Rivero, Marisa Iborra, María González-Vivo, Isabel Vera, Luisa de Castro, Luis Bujanda, Manuel Barreiro-de Acosta, Carlos González-Muñoza, Xavier Calvet, José Manuel Benítez, Mónica Llorente-Barrio, Gerard Surís, Fiorella Cañete, Lara Arias-García, David Monfort, Andrés Castaño-García, Francisco Javier Garcia-Alonso, José M. Huguet, Ignacio Marín-Jímenez, Rufo Lorente, Albert Martín-Cardona, Juan Ángel Ferrer, Patricia Camo, Javier P. Gisbert, Ramón Pajares, Fernando Gomollón, Jesús Castro-Poceiro, Jair Morales-Alvarado, Jordina Llaó, Andrés Rodríguez, Cristina Rodríguez, Pablo Pérez-Galindo, Mercè Navarro, Nuria Jiménez-García, Marta Carrillo-Palau, Isabel Blázquez-Gómez, Eva Sesé, Pedro Almela, Patricia Ramírez de la Piscina, Carlos Taxonera, Iago Rodríguez-Lago, Lidia Cabrinety, Milagros Vela, Miguel Mínguez, Francisco Mesonero, María José García, Mariam Aguas, Lucía Márquez, Marisol Silva Porto, Juan R. Pineda, Koldo García-Etxebarría, Federico Bertoletti, Eduard Brunet, Míriam Mañosa, and Eugeni Domènech

Subjects
Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Background: Infliximab seems to be the most efficacious of the three available anti-TNF agents for ulcerative colitis (UC) but little is known when it is used as the second anti-TNF. Objectives: To compare the clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in UC patients. Design: Retrospective observational study. Methods: Patients from the ENEIDA registry treated consecutively with infliximab and a subcutaneous anti-TNF (or vice versa), naïve to other biological agents, were identified and grouped according to the administration route of the first anti-TNF into IVi (intravenous initially) or SCi (subcutaneous initially). Results: Overall, 473 UC patients were included (330 IVi and 143 SCi). Clinical response at week 14 was 42.7% and 48.3% in the IVi and SCi groups (non-statistically significant), respectively. Clinical remission rates at week 52 were 32.8% and 31.4% in the IVi and SCi groups (nonsignificant differences), respectively. A propensity-matched score analysis showed a higher clinical response rate at week 14 in the SCi group and higher treatment persistence in the IVi group. Regarding long-term outcomes, dose escalation and discontinuation due to the primary failure of the first anti-TNF and more severe disease activity at the beginning of the second anti-TNF were inversely associated with clinical remission. Conclusion: The use of a second anti-TNF for UC seems to be reasonable in terms of efficacy, although it is particularly reduced in the case of the primary failure of the first anti-TNF. Whether the second anti-TNF is infliximab or subcutaneous does not seem to affect efficacy.

Published
2024
Full Text
View/download PDF

3. Noticias y revisión bibliográfica

Author

Rafael J. García-Villanova, Javier Reinares Ortiz de Villajos, Juan Ángel Ferrer Azcona, and Óscar Martínez Jiménez

Subjects
Medicine
Abstract

No disponible.

Published
2023

4. Noticias y revisión bibliográfica

Author

Rafael J. García-Villanova, Javier Reinares Ortiz de Villajos, Juan Ángel Ferrer Azcona, Óscar Martínez Jiménez, Claudia J. Álvarez-Garcillán Padruno, Blanca González Lavín, Claudia Hidalgo Prieto, Marian Lozano Yagüe, María Ponce Renilla, María Barberá-Riera, Juan Carlos Gascó Laborda, Rosa de Llanos, Félix Hernández, and Juana María Delgado-Saborit

Subjects
Medicine
Abstract

No disponible.

Published
2022

7. Broth microdilution protocol for determining antimicrobial susceptibility of Legionella pneumophila to clinically relevant antimicrobials

Author

Afzal, Amna, Allam, Camille, Amemura-Maekawa, Junko, Andersson, Sabina, Pérez, Elisenda Arqué, Astrid, Muyldermans, Bangsborg, Jette Marie, Bargellini, Annalisa, Barna, Zsófia, Beeton, Michael, Bigler, Mellina, Bošnjak, Selma, Brandsema, Petra, Brewin, Brett, Broger, Tobias, Brown, Derek, Coroneo, Valentina, Rotger, Sebastian Crespi, Cristino, Sandra, De Jong, Birgitta, Demuyser, Thomas, Doniselli, Nicola, Surman-Lee, Susanne, Elverdal, Pernille L., Erdogan, Haluk, Eriksen, Helle, Euser, Sjoerd, Fermi, Beatrice, Azcona, Juan Angel Ferrer, Franzin, Laura, Goldenberg, Simon, Gonçalves, Paulo, Fernandez, Tiscar Graells, Haider, Julia, Henderson, Kelley, Ibranosyan, Marine, Joergensen, Charlotte Svaerke, Jomidava, Tinatin, Jovanovic, Milica, Jowitt, Maddy, Katsemi, Evdokia, Keynan, Yoav, Kieper, Laurine, Kindingstad, Louise, Kozak-Muiznieks, Natalia, Kunwar, Digbijay, Kura, Fumiaki, Kyritsi, Maria, Lee, John Vincent, Löhr, Iren Høyland, Majeska, Kristin, Mäusezahl, Daniel, Mendris, Michail, Michel, Charlotte, Moore, Ginny, Moretti, Marco, Mustermann, Maximilian Test, Naguthevar, Santhanam, Paduano, Stefania, Niño, Noemí Párraga, Pedro-Botet, Maria Luisa, Castro, Sonia Perez, Pissarides, Nicholas, Prevost, Michele, Reukers, Daphne, Robesyn, Emmanuel, Schönning, Caroline, Simone, Graf, Stuart, Adam, Templeton, Kate, Topalli, Claudia, Uhle, Sarah, Uldum, Søren, Van Honacker, Eveline, Veschetti, Enrico, Walker, Jimmy, Wallet, France, Wasserstrom, Lisa, Whapham, Catherine, Wybo, Ingrid, Zoued, Abdelrahim, Sewell, Max, Farley, Caitlin, Portal, Edward A.R., Lindsay, Diane, Ricci, Maria Luisa, Jarraud, Sophie, Scaturro, Maria, Descours, Ghislaine, Krøvel, Anne Vatland, Barton, Rachael, Boostom, Ian, Ure, Roisin, Kese, Darja, Gaia, Valeria, Golob, Matej, Paukner, Susanne, Ginevra, Christophe, Afshar, Baharak, Nadarajah, Sendurann, Echahdi, Fedoua, González-Rubio, Juana María, González-Camacho, Fernando, Mentasti, Massimo, Flountzi, Anastasia S., Petzold, Markus, Moran-Gilad, Jacob, Winchell, Jonas, Wooton, Mandy, Bernard, Kathryn, Jones, Lucy C., Chalker, Victoria J., and Spiller, Owen B.

Published
2025
Full Text
View/download PDF

8. 67 - PSORIASIS INDUCIDA POR TERAPIA ANTI-TNF EN ENFERMEDAD INFLAMATORIA INTESTINAL: ANÁLISIS DEL MANEJO TERAPÉUTICO Y EVOLUCIÓN DE AMBAS ENFERMEDADES EN UN ESTUDIO DE COHORTES A NIVEL NACIONAL

Author

Segura, Patricia Sanz, Gomollón, Fernando, Argumánez, Víctor, Vela, Milagros, Fernández-Clotet, Agnès, Muñoz, Roser, de la Filia, Irene García, Prada, María García, Rosique, Juan Ángel Ferrer, García, María José, de Francisco, Ruth, Arias, Lara, Barrio, Jesús, Guerra, Iván, Diaz, Ángel Ponferrada, Gisbert, Javier P., Carrillo-Palau, Marta, Calvet, Xavier, Mosquera, Lucía Márquez, Gros, Beatriz, Cañete, Fiorella, Monfort, David, Domínguez, Rosa Eva Madrigal, Roncero, Óscar, Laredo, Viviana, Montoro, Miguel, Muñoz, Carmen, López-Cauce, Beatriz, Lorente, Rufo, Coronel, Ana Fuentes, Vega, Pablo, Martín-Arranz, María Dolores, Peña, Elena, Varela, Pilar, Casas-Deza, Diego, Olivares, Sonsoles, Pajares, Ramón, Lucendo, Alfredo J., Abizanda, Eva Sesé, Mateu, Belén Botella, García, Sonia García, Domènech, Eugeni, and García-López, Santiago

Published
2023
Full Text
View/download PDF

9. 33 - LA INFECCIÓN POR VIH SE ASOCIA CON UN FENOTIPO MENOS AGRESIVO DE ENFERMEDAD INFLAMATORIA INTESTINAL. ESTUDIO MULTICÉNTRICO BASADO EN EL REGISTRO ENEIDA

Author

Calafat, Margalida, Súria, Carles, Mesonero, Francisco, de Francisco, Ruth, Caballero, Carmen Yagüe, de la Peña, Luisa, Camba, Alejandro Hernández, Marcè, Ainhoa, Llera, Beatriz Gallego, Martín-Vicente, Noelia, Rivero, Montserrat, Iborra, Marisa, Guerra, Iván, Carrillo-Palau, Marta, Madero, Lucía, Burgueño, Beatriz, Montfort, David, Torres, Gisela, Teller, Marta, Rosique, Juan Ángel Ferrer, Villaamil, Pablo Vega, Roig, Cristina, Ponferrada, Ángel, Glaría, Elena Betoré, Zabana, Yamile, Gisbert, Javier P., Busquets, David, Alcaide, Noelia, Camps, Blau, Legido, Jesús, Vivo, Maria González, Bosca-Watts, Marta Maia, Pérez-Martínez, Isabel, Deza, Diego Casas, Guardiola, Jordi, Hernández, Laura Arranz, Navarro-Llavat, Mercè, Gomollón, Fernando, Cañete, Fiorella, Mañosa, Míriam, and Domènech, Eugeni

Published
2023
Full Text
View/download PDF

10. Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon?

Author

Sonia Alonso, Adriana-René Guerra, Lourdes Carreira, Juan-Ángel Ferrer, María-Luisa Gutiérrez, and Conrado M. Fernandez-Rodriguez

Subjects
Hepatitis B virus clearance, Latest pharmacological developments, HBV cccDNA, HBV functional cure, HBV eradication, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Abstract Background Hepatitis B virus (HBV) chronic infection affects up to 240 million people in the world and it is a common cause of cirrhosis and hepatocellular carcinoma (HCC). HBV covalently closed circular DNA (cccDNA) plays an essential role in HBV persistence and replication. Current pharmacological treatment with nucleos(t)ide analogues (NA) may suppress HBV replication with little or no impact on cccDNA, hence lifelong treatment is required in the vast majority of patients. Clearances of intrahepatic cccDNA and/or HBsAg are critical endpoints for future antiviral therapy in chronic HBV. Recent promising developments targeting different molecular HBV life cycle steps are being pre-clinically tested or have moved forward in early clinical trials. Methods We review the current state of the art of these pharmacological developments, mainly focusing on efficacy and safety results, which are expected to lay the ground for future HBV eradication. An inclusive literature search on new treatments of HBV using the following electronic databases: Pubmed/MEDLINE, AMED, CINAHL and the Cochrane Central Register of Controlled Trials. Full-text manuscripts and abstracts published over the last 12 years, from 2005 to March 2011 were reviewed for relevance and reference lists were crosschecked for additional applicable studies regarding new HBV antiviral treatment. Results HBV entry inhibitors, HBV core inhibitors, HBV cccDNA transcripts RNA interference, HBV cell apoptosis inducers, HBV RNA, viral proteins and DNA knock down agents, HBV release inhibitors, anti-sense nucleosides, exogenous interferon stimulation, interferon response stimulation and HBV therapeutic vaccines were reviewed. Conclusion This review will provide readers with an updated vision of current and foreseeable therapeutic developments in chronic hepatitis B.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results